Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

905 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Kim ST, Smith SA, Mortimer P, Loembé AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J. Kim ST, et al. Among authors: dean e. Clin Cancer Res. 2021 Sep 1;27(17):4700-4709. doi: 10.1158/1078-0432.CCR-21-0251. Epub 2021 May 11. Clin Cancer Res. 2021. PMID: 33975862 Free PMC article. Clinical Trial.
A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
Molife LR, Dean EJ, Blanco-Codesido M, Krebs MG, Brunetto AT, Greystoke AP, Daniele G, Lee L, Kuznetsov G, Myint KT, Wood K, de Las Heras B, Ranson MR. Molife LR, et al. Clin Cancer Res. 2014 Dec 15;20(24):6284-94. doi: 10.1158/1078-0432.CCR-14-0409. Epub 2014 Oct 2. Clin Cancer Res. 2014. PMID: 25278451 Clinical Trial.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. Banerji U, et al. Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24. Clin Cancer Res. 2018. PMID: 29066505 Clinical Trial.
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM. McMullen M, et al. Among authors: dean e. Int J Gynecol Cancer. 2020 Nov;30(11):1824-1828. doi: 10.1136/ijgc-2020-001694. Epub 2020 Sep 2. Int J Gynecol Cancer. 2020. PMID: 32878963 Free PMC article.
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, Berges A, Cheung SYA, Irurzun-Arana I, Goldwin A, Felicetti B, Jones GN, Lau A, Frewer P, Pierce AJ, Clack G, Stephens C, Smith SA, Dean E, Hollingsworth SJ. Yap TA, et al. Among authors: dean e. Clin Cancer Res. 2021 Oct 1;27(19):5213-5224. doi: 10.1158/1078-0432.CCR-21-1032. Clin Cancer Res. 2021. PMID: 34301752 Free PMC article. Clinical Trial.
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Mahdi H, et al. Among authors: dean e. JCO Precis Oncol. 2021 Sep 7;5:PO.20.00439. doi: 10.1200/PO.20.00439. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34527850 Free PMC article. Clinical Trial.
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F. Shah PD, et al. Among authors: dean e. Gynecol Oncol. 2021 Nov;163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Epub 2021 Oct 5. Gynecol Oncol. 2021. PMID: 34620496 Free PMC article. Clinical Trial.
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN. Willis SE, et al. Among authors: dean e. Br J Cancer. 2021 Dec;125(12):1666-1676. doi: 10.1038/s41416-021-01560-1. Epub 2021 Oct 18. Br J Cancer. 2021. PMID: 34663950 Free PMC article.
905 results